Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147094 | 0.89 | KDM4E (0.59) | PTGDR2LMNAKMT2AMAPTKDM4E | |
| SCHEMBL2225179 | 0.89 | LMNA (0.57) | PTGDR2LMNAKMT2AMAPTKDM4E | |
| SCHEMBL11280545 | 0.86 | HTT (0.51) | PTGDR2LMNAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL9774357 | 0.86 | PTGDR2 (0.54) | PTGDR2LMNAKMT2AMAPTKDM4E | |
| SCHEMBL13064183 | 0.84 | TSHR (0.64) | LMNAKMT2AMAPTKDM4EPOLB | |
| SCHEMBL13755295 | 0.84 | MAPT (0.48) | PTGDR2KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL4199370 | 0.83 | MAPT (0.55) | PTGDR2KMT2AMAPTKDM4EPOLB | |
| SCHEMBL4051742 | 0.82 | ALDH1A1 (0.52) | PTGDR2KMT2AMAPTKDM4EHSD17B10 | |
| SCHEMBL9855260 | 0.82 | PTGDR2 (0.68) | PTGDR2LMNAKMT2AMAPTKDM4E | |
| SCHEMBL29184850 | 0.82 | PTGDR2 (0.58) | PTGDR2LMNAKMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105164112-A | Amide compound and preparation method, pharmaceutical composition and application thereof | SHANGHAI INST MATERIA MEDICA | 2015-12-16 | — | — | CN | disclosed |
| CN-102015641-B | Heterocyclic compound | TAKEDA PHARMACEUTICAL | 2014-01-01 | — | — | CN | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | PTGDR2 1217/4885LMNA 3028/4885KMT2A 1298/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | PTGDR2 1217/4885LMNA 3028/4885KMT2A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.